FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089094196> ?p ?o ?g. }

• W3089094196 endingPage "e707" @default.
• W3089094196 startingPage "e707" @default.
• W3089094196 abstract "We read with interest the report by Nagesh Kalakonda and colleagues of the SADAL trial 1 Kalakonda N Maerevoet M Cavallo F et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020; 7: e511-e522 Summary Full Text Full Text PDF PubMed Scopus (133) Google Scholar of selinexor for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The novel mechanism of selinexor and the 15 (12%) complete responses observed in 127 patients in the study suggest that the drug could be promising in certain subgroups of patients with relapsed or refractory DLBCL. However, the subgroups that are likely to benefit remain to be identified, and the SADAL population might not be representative of all patients with relapsed or refractory DLBCL. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trialSingle-drug oral selinexor induced durable responses and had a manageable adverse events profile in patients with relapsed or refractory DLBCL who received at least two lines of previous chemoimmunotherapy. Selinexor could be considered a new oral, non-cytotoxic treatment option in this setting. Full-Text PDF Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact – Authors' replyIn response to the Correspondence from Stephen Smith and Ajay Gopal, we contend that the patients enrolled in the SADAL trial1 were not atypical of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This contention is best supported by the finding that the median overall survival time of patients with progressive disease or a non-evaluable response was 4·3 months (95% CI 3·0–5·4). This time is shorter than what was anticipated on the basis of data from the SCHOLAR-1 study,2 which showed median overall survival times of around 5–6 months across cohorts of patients with relapsed or refractory DLBCL. Full-Text PDF" @default.
• W3089094196 created "2020-10-01" @default.
• W3089094196 creator A5004025497 @default.
• W3089094196 creator A5088459737 @default.
• W3089094196 date "2020-10-01" @default.
• W3089094196 modified "2023-10-18" @default.
• W3089094196 title "Selinexor for relapsed or refractory diffuse large B-cell lymphoma: examining the artifact" @default.
• W3089094196 cites W2117460825 @default.
• W3089094196 cites W2984927918 @default.
• W3089094196 cites W3037697670 @default.
• W3089094196 cites W4232890019 @default.
• W3089094196 doi "https://doi.org/10.1016/s2352-3026(20)30290-8" @default.
• W3089094196 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32976744" @default.
• W3089094196 hasPublicationYear "2020" @default.
• W3089094196 type Work @default.
• W3089094196 sameAs 3089094196 @default.
• W3089094196 citedByCount "2" @default.
• W3089094196 countsByYear W30890941962021 @default.
• W3089094196 crossrefType "journal-article" @default.
• W3089094196 hasAuthorship W3089094196A5004025497 @default.
• W3089094196 hasAuthorship W3089094196A5088459737 @default.
• W3089094196 hasConcept C121332964 @default.
• W3089094196 hasConcept C126322002 @default.
• W3089094196 hasConcept C142424586 @default.
• W3089094196 hasConcept C143998085 @default.
• W3089094196 hasConcept C2778559949 @default.
• W3089094196 hasConcept C2779338263 @default.
• W3089094196 hasConcept C2780653079 @default.
• W3089094196 hasConcept C2780790343 @default.
• W3089094196 hasConcept C2908647359 @default.
• W3089094196 hasConcept C31760486 @default.
• W3089094196 hasConcept C535046627 @default.
• W3089094196 hasConcept C71924100 @default.
• W3089094196 hasConcept C87355193 @default.
• W3089094196 hasConcept C99454951 @default.
• W3089094196 hasConceptScore W3089094196C121332964 @default.
• W3089094196 hasConceptScore W3089094196C126322002 @default.
• W3089094196 hasConceptScore W3089094196C142424586 @default.
• W3089094196 hasConceptScore W3089094196C143998085 @default.
• W3089094196 hasConceptScore W3089094196C2778559949 @default.
• W3089094196 hasConceptScore W3089094196C2779338263 @default.
• W3089094196 hasConceptScore W3089094196C2780653079 @default.
• W3089094196 hasConceptScore W3089094196C2780790343 @default.
• W3089094196 hasConceptScore W3089094196C2908647359 @default.
• W3089094196 hasConceptScore W3089094196C31760486 @default.
• W3089094196 hasConceptScore W3089094196C535046627 @default.
• W3089094196 hasConceptScore W3089094196C71924100 @default.
• W3089094196 hasConceptScore W3089094196C87355193 @default.
• W3089094196 hasConceptScore W3089094196C99454951 @default.
• W3089094196 hasIssue "10" @default.
• W3089094196 hasLocation W30890941961 @default.
• W3089094196 hasLocation W30890941962 @default.
• W3089094196 hasOpenAccess W3089094196 @default.
• W3089094196 hasPrimaryLocation W30890941961 @default.
• W3089094196 hasRelatedWork W1984872172 @default.
• W3089094196 hasRelatedWork W2007548746 @default.
• W3089094196 hasRelatedWork W2031218360 @default.
• W3089094196 hasRelatedWork W2272592620 @default.
• W3089094196 hasRelatedWork W2469233091 @default.
• W3089094196 hasRelatedWork W2956272503 @default.
• W3089094196 hasRelatedWork W3001665703 @default.
• W3089094196 hasRelatedWork W4248093231 @default.
• W3089094196 hasRelatedWork W4294943818 @default.
• W3089094196 hasRelatedWork W893134433 @default.
• W3089094196 hasVolume "7" @default.
• W3089094196 isParatext "false" @default.
• W3089094196 isRetracted "false" @default.
• W3089094196 magId "3089094196" @default.
• W3089094196 workType "article" @default.